Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial.
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized
/ administration & dosage
Antineoplastic Agents, Immunological
/ administration & dosage
Carcinoma, Renal Cell
/ drug therapy
Female
Humans
Kaplan-Meier Estimate
Kidney Neoplasms
/ drug therapy
Male
Middle Aged
Neoplasm Metastasis
Neoplasm Staging
Prognosis
Treatment Outcome
Avelumab
Metastatic
PD-L1
Phase I
Renal cell carcinoma
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
24 10 2019
24 10 2019
Historique:
received:
31
05
2019
accepted:
20
09
2019
entrez:
26
10
2019
pubmed:
28
10
2019
medline:
14
7
2020
Statut:
epublish
Résumé
Antibodies targeting programmed death-1 (PD-1) or programmed death-ligand 1 (PD-L1) have shown clinical activity in the treatment of metastatic renal cell carcinoma (mRCC). This phase Ib cohort of the JAVELIN Solid Tumor trial assessed the efficacy and safety of avelumab (anti-PD-L1) monotherapy in patients with mRCC as either first-line (1 L) or second-line (2 L) treatment. Patients with mRCC with a clear-cell component who were treatment naive (1 L subgroup) or had disease progression after one prior line of therapy (2 L subgroup) received avelumab 10 mg/kg intravenous infusion every 2 weeks. Endpoints included confirmed best overall response, duration of response (DOR), progression-free survival (PFS), overall survival (OS), PD-L1 expression, and safety. A total of 62 patients were enrolled in the 1 L subgroup, and 20 patients were enrolled in the 2 L subgroup. In the 1 L and 2 L subgroups, confirmed objective response rates were 16.1 and 10.0%, median DOR was 9.9 months (95% confidence interval [CI], 2.8-not evaluable) and not evaluable (95% CI, 6.9-not evaluable), median PFS was 8.3 months (95% CI, 5.5-9.5) and 5.6 months (95% CI, 2.3-9.6), and median OS was not evaluable (95% CI, not evaluable) and 16.9 months (95% CI, 8.3-not evaluable), respectively. Treatment-related adverse events (TRAEs) of any grade occurred in 51 patients in the 1 L subgroup (82.3%) and 14 patients in the 2 L subgroup (70.0%). Grade ≥ 3 TRAEs occurred in eight patients in the 1 L subgroup (12.9%) and one patient in the 2 L subgroup (5.0%). No treatment-related deaths occurred. Avelumab showed clinical activity and a manageable safety profile in both the 1 L and 2 L treatment setting in patients with mRCC. These data support the use of avelumab in combination with other agents in mRCC. ClinicalTrials.gov: NCT01772004 ; registered 21 January, 2013.
Sections du résumé
BACKGROUND
Antibodies targeting programmed death-1 (PD-1) or programmed death-ligand 1 (PD-L1) have shown clinical activity in the treatment of metastatic renal cell carcinoma (mRCC). This phase Ib cohort of the JAVELIN Solid Tumor trial assessed the efficacy and safety of avelumab (anti-PD-L1) monotherapy in patients with mRCC as either first-line (1 L) or second-line (2 L) treatment.
METHODS
Patients with mRCC with a clear-cell component who were treatment naive (1 L subgroup) or had disease progression after one prior line of therapy (2 L subgroup) received avelumab 10 mg/kg intravenous infusion every 2 weeks. Endpoints included confirmed best overall response, duration of response (DOR), progression-free survival (PFS), overall survival (OS), PD-L1 expression, and safety.
RESULTS
A total of 62 patients were enrolled in the 1 L subgroup, and 20 patients were enrolled in the 2 L subgroup. In the 1 L and 2 L subgroups, confirmed objective response rates were 16.1 and 10.0%, median DOR was 9.9 months (95% confidence interval [CI], 2.8-not evaluable) and not evaluable (95% CI, 6.9-not evaluable), median PFS was 8.3 months (95% CI, 5.5-9.5) and 5.6 months (95% CI, 2.3-9.6), and median OS was not evaluable (95% CI, not evaluable) and 16.9 months (95% CI, 8.3-not evaluable), respectively. Treatment-related adverse events (TRAEs) of any grade occurred in 51 patients in the 1 L subgroup (82.3%) and 14 patients in the 2 L subgroup (70.0%). Grade ≥ 3 TRAEs occurred in eight patients in the 1 L subgroup (12.9%) and one patient in the 2 L subgroup (5.0%). No treatment-related deaths occurred.
CONCLUSION
Avelumab showed clinical activity and a manageable safety profile in both the 1 L and 2 L treatment setting in patients with mRCC. These data support the use of avelumab in combination with other agents in mRCC.
TRIAL REGISTRATION
ClinicalTrials.gov: NCT01772004 ; registered 21 January, 2013.
Identifiants
pubmed: 31651359
doi: 10.1186/s40425-019-0746-2
pii: 10.1186/s40425-019-0746-2
pmc: PMC6813090
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Antineoplastic Agents, Immunological
0
avelumab
KXG2PJ551I
Banques de données
ClinicalTrials.gov
['NCT01772004']
Types de publication
Clinical Trial, Phase I
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
275Références
Am J Clin Exp Urol. 2015 Aug 08;3(2):77-90
pubmed: 26309897
Lancet Oncol. 2018 Apr;19(4):451-460
pubmed: 29530667
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
J Immunother Cancer. 2019 Jan 16;7(1):12
pubmed: 30651126
Crit Rev Oncol Hematol. 2015 Dec;96(3):527-33
pubmed: 26299335
Clin Exp Med. 2018 May;18(2):165-175
pubmed: 29362922
Lancet Oncol. 2018 Jan;19(1):51-64
pubmed: 29217288
J Immunother Cancer. 2018 Oct 22;6(1):111
pubmed: 30348224
Lancet. 2019 Jun 15;393(10189):2404-2415
pubmed: 31079938
Cancers (Basel). 2011 Oct 26;3(4):4010-23
pubmed: 24213122
J Immunother Cancer. 2019 Feb 4;7(1):30
pubmed: 30717797
Lancet Oncol. 2017 May;18(5):587-598
pubmed: 28373007
N Engl J Med. 2019 Mar 21;380(12):1116-1127
pubmed: 30779529
Clin Sci (Lond). 2017 Oct 27;131(21):2627-2642
pubmed: 29079639
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
JAMA Oncol. 2019 Mar 1;5(3):393-401
pubmed: 30676622
Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):709s-715s
pubmed: 17255298
Target Oncol. 2016 Apr;11(2):143-8
pubmed: 26429561
N Engl J Med. 2019 Mar 21;380(12):1103-1115
pubmed: 30779531
N Engl J Med. 2017 Jan 26;376(4):354-366
pubmed: 28121507
Oncologist. 2011;16 Suppl 2:14-22
pubmed: 21346036
JAMA Oncol. 2019 Mar 1;5(3):351-357
pubmed: 30605211
Lancet Oncol. 2017 May;18(5):599-610
pubmed: 28373005
Nat Med. 2018 Jun;24(6):749-757
pubmed: 29867230
J Biomed Res. 2018 Sep 29;32(5):317-326
pubmed: 28866656
Lancet Oncol. 2018 Mar;19(3):405-415
pubmed: 29439857